Early use of abiraterone and radium-223 in metastatic prostate cancer

Lancet Oncol. 2019 May;20(5):e228. doi: 10.1016/S1470-2045(19)30226-8.

Authors

Maria Concetta Cursano¹, Daniele Santini², Michele Iuliani², Giovanni Paganelli³, Ugo De Giorgi⁴

Affiliations

¹ Department of Medical Oncology, Campus Bio-Medico University of Rome, 00128 Rome, Italy. Electronic address: m.cursano@unicampus.it.
² Department of Medical Oncology, Campus Bio-Medico University of Rome, 00128 Rome, Italy.
³ Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
⁴ Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.

PMID: 31044705
DOI: 10.1016/S1470-2045(19)30226-8

No abstract available

Publication types

Letter
Comment

MeSH terms

Abiraterone Acetate
Androstenes
Double-Blind Method
Humans
Male
Prednisolone
Prednisone
Prostatic Neoplasms, Castration-Resistant*
Radium*

Substances

Androstenes
Radium-223
Prednisolone
Abiraterone Acetate
abiraterone
Prednisone
Radium